Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Vaccine Industry Group Calls for Govt’s Control Functions for Infectious Diseases
April 21, 2021
- Japan Officially Announces CEA-Based Prices for Kymriah/Trelegy, Effective July 1
April 21, 2021
- FPMAJ Chief Calls for Uninterrupted Govt Support for Japan-Made Vaccines Even in Ordinary Times
April 20, 2021
- Over 50% of Itraconazole ADR Reporting Comes from Pharmacists in October-December: PMDA
April 20, 2021
- Automatic Listing for Approved Drugs Erodes Financial Predictability: MOF
April 19, 2021
- MHLW to Revoke Approval of 12 Kobayashi Kako Products as Documents Fabricated
April 19, 2021
- Industry Veteran Prods Appropriate Evaluation for Innovation: LDP Confab
April 16, 2021
- Chuikyo Receives Report on Fertility Treatment Survey, Awaits Guidelines to Discuss Coverage
April 16, 2021
- 2 New Payer Members Make Chuikyo Debut
April 15, 2021
- Ultomiris Now Braced for Price Cut as Chuikyo OKs CEA Results
April 15, 2021
- LDP Project Team to Compile Proposal on Japan-Made Vaccine Development
April 15, 2021
- Bayer’s Heart Failure Med Vericiguat Up for 2nd PAFSC Review
April 15, 2021
- MHLW Presents Discussion Timeline for FY2022 Reform
April 15, 2021
- Olumiant Up for PAFSC Review for COVID-19 on April 21, Combo Use with Veklury
April 15, 2021
- Drug Pricing Rules to Be Applied to Breyanzi: Chuikyo
April 15, 2021
- Yescarta to Join NHI Price List on April 21, Gets CEA-Tweak from Get-Go
April 14, 2021
- Kymriah to Get 4.3% Reduction, Trelegy 0.5% Cut in 1st CEA-Based Price Tweak
April 14, 2021
- 11 APIs to Get NHI Price Listing on April 21, 17 Billion Yen Peak Sales Projected for Lilly’s Migraine Med
April 14, 2021
- Novo’s Growth Hormone, Fujimoto’s Hemophilia Med Skip April Listing
April 14, 2021
- Japan to Prioritize Screening for N501Y Variant; E484K “Does Not Render Vaccines Ineffective”: Minister
April 14, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…